In Segment A, members will acquire distinct doses and schedules of oral ABBV-744 pill to establish Protected dosing routine. Supplemental individuals are going to be enrolled on the determined monotherapy dosign program. In Phase B, participants will acquire oral ruxolitinib and ABBV-744 will probably be presented as "increase-on" therapy. In https://abbv-744-combination-ther67901.blogchaat.com/32091624/facts-about-new-advancements-in-brd4-inhibition-therapy-abbv-744-revealed